卡瑞利珠单抗联合化疗一线治疗晚期无敏感基因突变肺腺癌的效果

Effect of Camrelizumab Combined with Chemotherapy in the First-Line Treatment of Advanced Lung Adenocarcinoma Without Sensitive Gene Mutation

目的探讨卡瑞利珠单抗联合培美曲塞及铂类一线治疗晚期无敏感基因突变肺腺癌的效果。方法回顾性分析2019年1月至2021年2月郑州大学第一附属医院收治的83例晚期无敏感基因突变的肺腺癌患者的临床资料。对照组(43例)接受化疗治疗,观察组(40例)接受卡瑞利珠单抗联合化疗治疗。比较两组临床疗效以及不良反应的发生情况。结果观察组的中位无进展生存时间(PFS,8.4个月)长于对照组(5.6个月),差异有统计学意义(P<0.05)。两组客观缓解率(ORR)及疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。观察组反应性毛细血管增生症(RCHs)发生率高于对照组(P<0.05),两组其他不良反应发生率及3级以上不良反应发生率比较,差异无统计学意义(P>0.05)。结论卡瑞利珠单抗联合化疗一线治疗无敏感基因突变的晚期肺腺癌的临床效果优于化疗,且不良反应发生率未明显升高。

Objective To investigate the clinical effect of camrelizumab combined with pemetrexed and platinum in the first-line treatment of advanced lung adenocarcinoma without sensitive gene mutation.Methods The clinical data of 83 patients with advanced lung adenocarcinoma without sensitive gene mutation admitted to the First Affiliated Hospital of Zhengzhou University from January 2019 to February 2021 were retrospectively analyzed.The control group(43 cases)received chemotherapy,while the observation group(40 cases)received camrelizumab combined with chemotherapy.The clinical efficacy and the incidence of adverse reactions were compared between the two groups.Results The median progression free survival time(PFS)of observation group(8.4 months)was longer than that of control group(5.6 months),and the difference was statistically significant(P<0.05).There was no statistical difference in objective response rate(ORR)and disease control rate(DCR)between the two groups(P>0.05).The incidence of reactive capillary hemangiomas(RCHs)of observation group was higher than that of control group(P<0.05).There was no statistical difference in the incidences of other adverse reactions and adverse reactions above grade 3 between the two groups(P>0.05).Conclusion The clinical effect of camrelizumab combined with chemotherapy in the first-line treatment of advanced lung adenocarcinoma without sensitive gene mutation is better than chemotherapy,and the incidence of adverse reactions has not increased significantly.